

## First reports of adverse drug reactions

© Springer Nature Switzerland AG 2023

Table 1 contains an overview of first published case reports of adverse drug reactions identified in the international literature in recent weeks by *Reactions Weekly*, the Adis drug safety newsletter. *Reactions Weekly* provides summaries of

adverse drug reaction news sourced from journals, scientific meetings, media releases, regulatory agency websites, and bulletins from the National Centers that participate in the WHO International Drug Monitoring Programme.

**Table 1** First reports of adverse drug reactions

Drug: event	Reference
Camrelizumab + lenvatinib: <i>Mycobacterium neoaurum</i> infection (serious)	Pang L, et al. Case report: <i>Mycobacterium neoaurum</i> infection during ICI therapy in a hepatocellular carcinoma patient with psoriasis. <a href="#">Front Immunol. 2022;13:972302</a>
Chorionic gonadotropin + follitropin alfa: psychiatric disorder (serious)	De Lorenzo Calzon M, et al. Psychotic reaction during the treatment of infertility with gonadotropins. <a href="#">Eur Psychiatry. 2019;56(Suppl 1):S3–321</a>
Cisplatin + gemcitabine: idiopathic hyperammonaemic encephalopathy (serious)	Verkerk K, et al. Idiopathic hyperammonemic encephalopathy secondary to gemcitabine-cisplatin treatment. <a href="#">Cancer Chemother Pharmacol. 2022;90(5):417–9</a>
Emicizumab: photosensitivity	Asensi Canto P, et al. Emicizumab-induced photosensitivity. <a href="#">TH Open. 2022;6(3):e154–5</a>
Emtricitabine/tenofovir disoproxil fumarate: oesophagitis <sup>a</sup> (serious)	Bonnichsen MH, et al. Pill related oesophagitis due to tenofovir disoproxil fumarate/emtricitabine (Truvada) HIV pre-exposure prophylaxis. <a href="#">Intern Med J. 2022;52(6):1099–100</a>
Imatinib + ponatinib: pneumonitis (serious)	Abouzeid M, et al. Ponatinib-induced pneumonitis: a first case report. <a href="#">Chest. 2022;162(4 Suppl):A704</a>
Silver nitrate: iatrogenic lipomembranous changes	Ravi SS, et al. Iatrogenic lipomembranous changes related to silver nitrate application. <a href="#">Am J Dermatopathol. 2022;44(Suppl 9):S8–9</a>

An event is serious (US FDA MedWatch definition) when the patient outcome is death, life threatening, hospitalization, disability, congenital anomaly or requires intervention to prevent permanent impairment or damage

<sup>a</sup>Following self-administration error